27 August 2020 in South Russian Journal of Cancer
Purpose of the study. Investigation of possible optimization of treatment in patients with breast cancer and cervical cancer with low-dose xenon therapy.Patients and methods. The study included 156 patients with pT1В2N0M0 cervical cancer (CC) and pT2N1M0 breast cancer (BC) of the reproductive age (29–45 years) after radical treatment, including forced surgical castration in hormone-positive breast cancer with concomitant gynecological pathology. Since the formation of pathological syndromes, 1 cycle (5 sessions) of low-dose xenon inhalation therapy (XT) was performed, with an algorithm for xenon dose calculation and exposure according to the exponential pattern of decreasing concentration and increasing exposure, with an individual approach. Together with general clinical and laboratory examinations, we used international scales for assessing the severity of the patient condition by the Kupperman menopausal index (MMI), ESAS, quality of life (MOS-SF-36), in a modification of the Russian International Center, pain (VAS); the types of general adaptive reactions were identified by the method of L.Kh. Garkavi.Results. Important advantages of a new method associated with a rapid regression of pathological psychosomatic symptoms were revealed after XT. MMI values (p<0.05) decreased, 96.8% of patients reported no pain at all on activity, manifestations of neurovegetative disorders significantly decreased (p=0.02–0.04), and the coefficient of antistress reactions to stress increased, which was congruent with the data on improving the quality of life. Conclusion. High efficiency of the technology demonstrated possible prevention of surgical menopause development and clinical manifestations of postcastration syndrome in order to improve the quality of life and social rehabilitation of young patients with gynecological cancers.
26 March 2023 in Research and Practical Medicine Journal
Purpose of the study. The purpose of the study was to evaluate the dynamics of parameters of malondialdehyde (MDA), reduced glutathione and antioxidant enzyme activity in patients with advanced cervical cancer (CC) receiving anticancer treatment with dendritic cell vaccine (DCV).Patients and methods. Levels of malondialdehyde (MDA), reduced glutathione and antioxidant enzyme activity were studied in 27 patients aged 27–65 years with advanced primary and recurrent CC receiving chemotherapy (CT) with DCV or DCV as monotherapy at a dose of 10 million cells intradermally once a week. The same indices were studied in 20 healthy women from the comparison group.Results. The majority of patients showed the initial increase of MDA: in blood plasma by an average of 66.7 %, in red blood cells – statistically insignificant. After CT, MDA levels were elevated respectively in primary and recurrent patients in erythrocytes by 85.6 % and 96.4 % compared to donors, and by 53.9 % and 33.7 % compared to the initial values; the levels in plasma were elevated by 79.8 % and 57.1 % compared to donors. After 5–7 DCVs in combination with CT, MDA levels in erythrocytes and in blood plasma were similar to the donor values. MDA in erythrocytes of patients receiving DCV without CT decreased by 36 % compared to initial values. Oxidase activity of ceruloplasmin, initially increased by 34.2–57.1 %, normalized after DCV. Superoxide dismutase activity decreased by 16.7–27.3 % after 4–6 DCVs and normalized after 7 DCVs. Catalase activity, initially reduced by more than 40 %, remained 20–38 % lower than the norm at all stages of DCV. In this setting, hydrogen peroxide was probably inactivated by glutathione peroxidase whose activity was increased at all stages of treatment and decreased only when MDA was normalized after 7 DCVs.Conclusion. Administration of 5–7 DCVs in combination with CT or as monotherapy to patients with advanced CC normalizes parameters of free radical oxidation and antioxidant system of the blood.
1 May 2019 in Voprosy onkologii
The aim was to study the possibility of normalizing rhythmic brain activity and psychoemotional status in young patients with locally advanced cervical cancer after surgical castration and the development of severe postovariectomic syndrome using low dose xenon therapy regimens. Material and methods. The study included data obtained from 30 patients aged 39.4±3.7 years with cervical cancer pT1bN0M0 (n=14), pT2aN0M0 (n=16); after the extirpation of the uterus with appendages and the upper third of the vagina with pelvic lymphadenectomy, patients received low-dose xenon therapy in an exponential programmed regimen of xenon concentration and exposure. The state of brain rhythms was controlled using the electroencephalograph-recorder “En-cephalan EEGR-19/26”. 19 unipolar leads were recorded with the calculation of the EEG spectral power and topographical mapping using the Encephalan-3D program. Psychological testing of patients with cervical cancer was performed using the questionnaires of 7-point individual subjective self-assessment developed by Garkavi L.Kh.- KuzmenkoT.S. Results. The normalizing effect of xenon therapy involved restructuring of cortical brain activity with a decrease in the power of slow- and high-frequency alpha-rhythm subranges and the predominance of physiologically significant mid-frequency alpha rhythms of 9.6 Hz quiet wakefulness together with slow delta and theta ranges. This correlated with the data of topographic mapping of the power spectrum on the presence of two foci of the spatial organization of alpha and theta rhythms. Evaluation criteria for psychological testing showed the reduction of anxiety, depression, fatigue, normalization of sleep, appetite, work capacity, and increased activity and optimism in 82-98% of patients. Conclusion. The possibility of inhibiting the postcastration syndrome in patients with cervical cancer is evidently realized through the xenon-induced effect of brain rhythmogenesis restructuring, leading to the normalization of impaired cortical-subcortical relationships and the formation of positive psycho-emotional status. The therapeutic expediency of low-dose xenon therapy for oncogynecological patients is determined by a significant correction of the state of the CNS state and the early achievement of functional and social rehabilitation.
17 January 2024 in Medical alphabet
Endometrial cancer (EC) is one of the most common cancers with a constantly and steadily growing incidence worldwide. The main reason for EC development, in addition to the female population aging, involves the obesity epidemic and associated hyperinsulinemia. Screening for EC has not been developed. However, endometrial carcinoma (ECa) demonstrates a specific symptomatology and clinical picture, and diagnostic methods are available, sensitive and defined by a certain range of comorbid diseases. These factors allow early ECa diagnosis in 80 %. The methods of treatment are standardized, depending on the stage of RTM and the morphological structure of EC, the age of the patient and allow to achieve 72–76 % of the overall 5-year survival rate. The methods of treatment are standardized, depending on the EC stage, the morphological structure of ECa, and the patient’s age, and allow achieving the 5-year overall survival of 72–76 %. The disease promised a favorable outcome and seemed to be controlled. However, at the end of the last century, researchers started to report the clinical and morphological heterogeneity of ECa, which allowed Ya. V. Bohman to propose a dichotomous division of EC into clinical and pathological variants. Such a division was accepted all over the world and required re-evaluation of the prognostic value of various endometrial adenocarcinoma histotypes depending on the phenotype and hormonogenesis of ECa. Initially, adenosquamous cancer (or endometrioid adenocarcinoma with squamous metaplasia, in the modern classification) was also classified as estrogen-dependent endometrioid adenocarcinoma, and squamous cell endometrial cancer was classified as an unfavorable type with a poor prognosis and without hormonal influence. Interest in the squamous cell component in dimorphic endometrial adenocarcinoma has repeatedly arisen over the past decades due to its unpredictable clinical course. The newest TCGA molecular classification of EC did not clarify the issues, but gave rise to new ones related to the etiology and carcinogenesis of this ECa histotype and its clinical interpretation.
1 January 2017 in Medical news of the North Caucasus
15 September 2018 in Advances in molecular oncology
Background. There are contradictory data on the detection of human papillomavirus (HPV) in the tumor tissue in endometrial cancer (EС). Objective: to assess HPV infection rates in EC tumor tissues and to establish the relationship between the status of HPV infection and tumor morphological characteristics. Materials and methods. 57 formalin-fixed paraffin-embedded (FFPE) tissue samples of EC patients aged 47–78 years were studied. HPV DNAs were found in 54.4 % of samples. Results and conclusion. We did not reveal an association between the HPV tumor status and age, metastasis or invasion depth. However, there was an interdependence between HPV infection and some morphological characteristics of the tumor: its histological type (adenocarcinomas with squamous cell differentiation were HPV-positive 1.8 times more frequent compared to adenocarcinomas without one; in the first case, tumor tissues were more often infected with HPV 16, and in the second case with HPV 18); tumor grade (in the total cohort and in serous-papillary adenocarcinomas, tumors with higher grades were more often HPV-infected: from 0 to 81.8 % and from 0 to 100 % respectively); disease stage (in the total cohort the percentage of HPV-positive tumors in stage II was 2.4 times and in stage III – 1.6 times higher than in stage I, and stage IA tumors were HPV-positive 2.3 times more often than IB tumors); type of tumor growth (tumors with infiltrative growth type were HPV-positive 1.7 times more often than with exophytic growth, and 2.2 times more often than with mixed growth). The achieved results do not allow us to conclude with confidence that HPV is the main tumor forming factor in EC.